Blog
RSS FeedPosted by Michael Wonder on 03 Sep 2018
How robots and ‘smart-bomb’ drugs saved dying baby Ellie
2 September 2018 - Just a year ago, Ellie Caterjian could barely breathe because the 11-month-old had a tumour the ...
Posted by Michael Wonder on 18 Jul 2018
$50 million to provide life-saving support to cancer patients
18 July 2018 - The Australian Government will provide $50 million to support some of Australia’s sickest patients, battling the most ...
Posted by Michael Wonder on 17 Jul 2018
Federal Government to announce $50 million custom cancer drug trial
17 July 2018 - Almost 600 Queenslanders will have their cancer’s DNA tested to identify the drugs that will keep ...
Posted by Michael Wonder on 12 Jul 2018
Opdivo + Yervoy: first combination immunotherapy for advanced renal cell carcinoma (kidney cancer) receives TGA approval
11 July 2018 - Opdivo now approved in Australia for ten indications across six cancer types. ...
Posted by Michael Wonder on 01 May 2018
Opdivo (nivolumab) is the first and only anti-PD-1 therapy approved by TGA for adjuvant treatment of melanoma
30 April 2018 - Opdivo now approved in Australia for nine indications across six cancer areas in under three years. ...
Posted by Michael Wonder on 23 Apr 2018
Celltrion’s Truxima approved in Australia
20 April 2018 - Celltrion said Sunday it has recently won approval from the Australia's Therapeutic Goods Administration for the ...
Posted by Michael Wonder on 16 Apr 2018
Provisional approval pathway - first determination decision
16 April 2018 - Olaratumab (Lartruvo) is the first medicine to be granted a provisional approval determination under the new ...
Posted by Michael Wonder on 05 Apr 2018
Specialised Therapeutics initiates early access program for neratinib maleate
5 April 2018 - Specialised Therapeutics today announces the initiation of an early access program for neratinib maleate an extended ...
Posted by Michael Wonder on 09 Mar 2018
Better support for patients with low survival cancers and diseases
9 March 2018 - The Australian Government is calling for applications from the country’s best and brightest researchers to help find ...
Posted by Michael Wonder on 07 Feb 2018
Priority review pathway - first registration decision
6 February 2018 - Alectinib hydrochloride (Alecensa) is the first medicine to be registered on the Australian Register of Therapeutic ...
Posted by Michael Wonder on 05 Feb 2018
Cancer research funding has an inherent bias that often excludes rare cancers, expert says
3 February 2018 - The biggest investor in cancer research in Australia needs to address an "inherent bias" in how ...
Posted by Michael Wonder on 23 Jan 2018
Registration of new chemical entities in Australia (update)
23 January 2018 - The TGA's publication of registration milestone dates facilitates more meaningful international comparisons. ...
Posted by Michael Wonder on 12 Dec 2017
It’s the law, not the Code – MA’s Director of Ethics and Compliance – Deborah Monk
12 December 2017 - The Director of Ethics and Compliance at Medicines Australia Ms Deborah Monk is troubled that there ...
Posted by Michael Wonder on 24 Aug 2017
Major new measures to help combat rare cancers
24 August 2017 - The Australian Government is supporting major new initiatives that will improve access to clinical trials, particularly for ...
Posted by Michael Wonder on 19 Jul 2017
Greens ban cancer medicine, gender in new sweeping policy platform
20 July 2017 - The Greens have plans to cut off production of cancer medications and remove questions about “gender” ...